VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases

Authors: Aline Maria Vasconcelos Queiroz, Johny Wysllas de Freitas Oliveira, Cláudia Jassica Moreno, Diego M.A.Guérin, Marcelo Sousa-Silva
Publication Year: 2021
Journal: Vaccines, 9(3), art 220, [Special Issue: Host Immune Response to Infectious Diseases pp 1 - 9]
Link: https://doi.org/10.3390/vaccines9030220

ABSTRACT Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine […]
Read More

Antibodies response induced by recombinant virus-like particles from Triatoma virus and chimeric antigens from Trypanosoma cruzi

ABSTRACT ‘Background:’ The infection caused by the protozoan Trypanosoma cruzi affects humans and is called as Chagas disease. Currently, the main measures available to reduce the incidence of this disease are drug treatment and vector control. Traditionally, the development of vaccines occurs mainly through the use of antigenic candidates of the etiologic agent in the […]
Read More

VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases

Antibodies response induced by recombinant virus-like particles from Triatoma virus and chimeric antigens from Trypanosoma cruzi

About GHTM

Contacts

Map